NCT03203421View on ClinicalTrials.gov

A Safety and Efficacy Study of ChAdOx1 LS2 and MVA LS2

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

July 3, 2017

Primary Completion Date

December 20, 2017

Study Completion Date

December 20, 2017

Conditions
Malaria
Interventions
BIOLOGICAL

ChAdOx1 LS2

A viral vectored vaccine, using a chimpanzee adenovirus as a vector encoding malaria liver-stage dual antigen LS2 (LSA1 and LSAP2) fused with the transmembrane domain from shark invariant chain.

BIOLOGICAL

MVA LS2

Modified vaccinia Ankara vector encoding liver-stage dual antigen LS2 (LSA1 ad LSAP2) fused to the C-terminal end of the leader sequence of tPA.

Trial Locations (1)

OX3 7LE

CCVTM, University of Oxford, Churchill Hospital, Oxford

All Listed Sponsors
lead

University of Oxford

OTHER

NCT03203421 - A Safety and Efficacy Study of ChAdOx1 LS2 and MVA LS2 | Biotech Hunter | Biotech Hunter